Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: Synthesis, structure-activity relationships, and X-ray crystal structure studies

被引:54
作者
Jadhav, PK [1 ]
Woerner, FJ [1 ]
Lam, PYS [1 ]
Hodge, CN [1 ]
Eyermann, CJ [1 ]
Man, HW [1 ]
Daneker, WF [1 ]
Bacheler, LT [1 ]
Rayner, MM [1 ]
Meek, JL [1 ]
Erickson-Viitanen, S [1 ]
Jackson, DA [1 ]
Calabrese, JC [1 ]
Schadt, M [1 ]
Chang, CH [1 ]
机构
[1] Dupont Merck Pharmaceut Co, Expt Stn, Chem & Phys Sci Dept, Wilmington, DE 19880 USA
关键词
D O I
10.1021/jm970524i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Comparison of the high-resolution X-ray structures of the native HIV-1 protease and its complexes with the inhibitors suggested that the enzyme flaps are flexible. The movement at the tip of the flaps could be as large as 7 Angstrom. On the basis of this observation, cyclic cyanoguanidines have been designed, synthesized, and evaluated as HIV-1 protease (PR) inhibitors. Cyclic cyanoguanidines were found to be very potent inhibitors of HIV-1 protease. The choice of cyclic cyanoguanidines over cyclic guanidines was based on the reduced basicity of the former. X-ray structure studies of the HIV PR complex with cyclic cyanoguanidine demonstrated that in analogy to cyclic urea, cyclic cyanoguanidines also displace the unique structural water molecule. The structure-activity relationship of the cyclic cyanoguanidines is compared with that of the corresponding cyclic urea analogues. The differences in binding constants of the two series of compounds have been rationalized using high-resolution X-ray structure information.
引用
收藏
页码:1446 / 1455
页数:10
相关论文
共 18 条
  • [1] ALA P, 1997, BIOCHEMISTRY-US, P1573
  • [2] AN ASSAY FOR HIV RNA IN INFECTED CELL LYSATES, AND ITS USE FOR THE RAPID EVALUATION OF ANTIVIRAL EFFICACY
    BACHELER, LT
    PAUL, M
    OTTO, MJ
    JADHAV, PK
    STONE, BA
    MILLER, JA
    [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1994, 5 (02) : 111 - 121
  • [3] CRYSTALLOGRAPHIC R-FACTOR REFINEMENT BY MOLECULAR-DYNAMICS
    BRUNGER, AT
    KURIYAN, J
    KARPLUS, M
    [J]. SCIENCE, 1987, 235 (4787) : 458 - 460
  • [4] 6-(SUBSTITUTED PHENYL)-5-METHYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONES OF MEDICINAL INTEREST - THE SYNTHESIS OF SK AND F-94836 AND SK AND F-95654
    BURPITT, BE
    CRAWFORD, LP
    DAVIES, BJ
    MISTRY, J
    MITCHELL, MB
    PANCHOLI, KD
    COATES, WJ
    [J]. JOURNAL OF HETEROCYCLIC CHEMISTRY, 1988, 25 (06) : 1689 - 1695
  • [5] THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS
    DEBOUCK, C
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) : 153 - 164
  • [6] POTENCY AND SELECTIVITY OF INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE BY A SMALL NONPEPTIDE C4 CYCLIC UREA, DMP-323
    ERICKSONVIITANEN, S
    KLABE, RM
    CAWOOD, PG
    ONEAL, PL
    MEEK, JL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) : 1628 - 1634
  • [7] FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209
  • [8] GANELLIN CR, 1982, CHRON DRUG DISCOVERY, V1, P1
  • [9] Improved cyclic urea inhibitors of the HIV-I protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
    Hodge, CN
    Aldrich, PE
    Bacheler, LT
    Chang, CH
    Eyermann, CJ
    Garber, S
    Grubb, M
    Jackson, DA
    Jadhav, PK
    Korant, B
    Lam, PYS
    Maurin, MB
    Meek, JL
    Otto, MJ
    Rayner, MM
    Reid, C
    Sharpe, TR
    Shum, L
    Winslow, DL
    EricksonViitanen, S
    [J]. CHEMISTRY & BIOLOGY, 1996, 3 (04): : 301 - 314
  • [10] JADHAV PK, 1997, IN PRESS BIOORG MED